<?xml version="1.0" encoding="UTF-8"?>
<p>The likelihood of experiencing an AE was higher under active treatment compared to placebo and was higher at higher doses. This, as well as the nature of the AEs (headache, flushing, nasal congestion, ocular hyperemia are among the most frequent TEAEs), reflects and can be well explained by the profile of the included predominantly vasoactive compounds: They mostly caused mode of action-related adverse effects closely related to the exposure and could be well monitored. </p>
